1. Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer
- Author
-
Sara Y. Brucker, Martin R. Sprick, Massimo Saini, Frederik Marmé, Markus Wallwiener, Florian Schütz, Dirk Jäger, Andreas Trumpp, Andreas Schneeweiss, Sabine Riethdorf, Sarah F. Jauch, TM Deutsch, Peter Sinn, Klaus Pantel, Juliane Nees, Birgitt Schönfisch, Christof Sohn, Barbara Burwinkel, and Lisa Becker
- Subjects
Adult ,0301 basic medicine ,Cancer Research ,Prognostic factor ,Breast Neoplasms ,Combinatorics ,03 medical and health sciences ,0302 clinical medicine ,Circulating tumor cell ,Biomarkers, Tumor ,Overall survival ,Enumeration ,medicine ,Humans ,In patient ,Prospective Studies ,neoplasms ,Aged ,Aged, 80 and over ,Physics ,Disease progression ,Middle Aged ,Neoplastic Cells, Circulating ,Prognosis ,medicine.disease ,Metastatic breast cancer ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Regression Analysis ,Female ,Stage iv - Abstract
Serial longitudinal enumeration of circulating tumor cells (CTCs) has shown its prognostic value on progression-free survival and overall survival (OS) in patients with stage IV breast cancer. This study prospectively evaluated the role of CTCs as a prognostic marker during further progression of metastatic breast cancer (MBC). Among 476 MBC patients recruited between 2010 and 2015, the 103 patients with a known CTC status at baseline (CTCBL) and within 4 weeks of tumor progression (CTCPD) were included. Progressive disease (PD) was defined according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1). Using the CellSearch method
- Published
- 2018
- Full Text
- View/download PDF